Literature DB >> 26866494

Voiding Dysfunction in Multiple Sclerosis.

Anton Wintner1, Michelle M Kim1, Seth K Bechis1, Evgeniy I Kreydin2.   

Abstract

Voiding dysfunction is a common and debilitating consequence of multiple sclerosis (MS). The prevalence and severity of voiding dysfunction increases with the increasing severity of MS, but even the mildest forms of the disease are associated with urinary symptoms in 30% of patients. Every component of the central nervous system is involved in regulating voiding; as a result, MS can lead to a wide variety of urinary symptoms and urologic complications. The effect of MS on voiding can be classified according to the resulting function of the bladder and the urethral sphincter during storage and emptying of urine. Therapy is targeted to the specific bladder and sphincter abnormalities that occur. The primary goals of therapy are prevention of injury to the upper urinary tract (kidneys), reduction in urinary tract infections, and maintenance of urinary continence. These goals can be achieved by interventions ranging from behavioral modification to major reconstructive surgery. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 26866494     DOI: 10.1055/s-0035-1571212

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  3 in total

Review 1.  Lower urinary tract dysfunction in common neurological diseases.

Authors:  Mohamad Moussa; Athanasios Papatsoris; Mohamed Abou Chakra; Yousef Fares; Athanasios Dellis
Journal:  Turk J Urol       Date:  2020-04-30

Review 2.  Botulinum Toxin Treatment in Multiple Sclerosis-a Review.

Authors:  Yasaman Safarpour; Tahereh Mousavi; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2017-08-17       Impact factor: 3.598

3.  Data-Driven Machine-Learning Quantifies Differences in the Voiding Initiation Network in Neurogenic Voiding Dysfunction in Women With Multiple Sclerosis.

Authors:  Christof Karmonik; Timothy Boone; Rose Khavari
Journal:  Int Neurourol J       Date:  2019-09-30       Impact factor: 2.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.